Table 3.

Risk of mortality and hazard ratios by HGF signature status, stratified by race and age in Carolina Breast Cancer study phase 1 and 2

	HGF	N (deaths)	Crude 5-year risk	*Standardized 5-year risk	*Standardized 5-year HR (95%CI)
Breast cancer specific mortality
	HGF-	428 (48)	11.21% (8.22, 14.21)	11.37% (8.12, 14.62)	Referent
	HGF+	278 (62)	22.30% (17.40,27.20)	20.09% (15.18, 24.99)	1.90 (1.26,2.85)
Non-Black	HGF-	257 (24)	9.34% (5.78, 12.90)	9.84% (5.91, 13.77)	Referent
	HGF+	99 (17)	17.17% (9.70, 24.64)	14.45% (7.45, 21.46)	1.52 (0.78,2.99)
Black	HGF-	171(24)	14.03% (8.81, 19.26)	13.79% (8.14, 19.44)	Referent
	HGF+	179 (45)	25.13% (18.77,31.52)	23.16% (16.66, 29.66)	1.80 (1.05, 3.09)
<50	HGF-	208 (32)	15.38% (10.47,20.29)	15.00% (9.87, 20.12)	Referent
	HGF+	181 (43)	23.76% (17.53,29.97)	21.51% (15.40, 27.63)	1.53 (0.94,2.50)
50+	HGF-	220 (16)	7.27 (3.83, 10.71)	6.95% (3.43, 10.47)	Referent
	HGF+	97 (19)	19.59% (11.64,27.52)	18.34% (10.39, 26.29)	2.81 (1.38,5.70)
Overall mortality
	HGF-	428 (66)	15.42% (11.99,18.85)	14.82% (11.24, 18.40)	Referent
	HGF+	278 (69)	24.82% (19.73,29.91)	23.29% (18.06, 28.52)	1.69 (1.17, 2.43)
Non-Black	HGF-	257 (34)	13.23% (9.07, 17.37)	12.48% (8.19, 16.76)	Referent
	HGF+	99 (18)	18.18% (10.54,25.81)	15.35% (8.18, 22.51)	1.28 (0.68,2.39)
Black	HGF-	171 (32)	18.71% (12.85,24.57)	18.53% (12.28, 24.78)	Referent
	HGF+	179 (51)	28.49% (21.86,35.12)	27.63% (20.66, 34.59)	1.60 (0.99,2.58)
<50	HGF-	208 (35)	16.83% (11.73,21.92)	16.54% (11.21, 21.86)	Referent
	HGF+	181 (44)	24.31% (18.04,30.58)	22.09% (15.91, 28.27)	1.43 (0.89,2.29)
50+	HGF-	220 (31)	14.09% (9.48, 18.70)	12.73% (8.15, 17.32)	Referent
	HGF+	97 (25)	25.77% (17.02,34.52)	24.75% (15.89, 33.61)	2.08 (1.19,3.64)

^*Mortality outcomes were standardized using inverse probability of exposure weights for age, and stage.